On September 19, 2025, the "Embarking on a Great Journey, A Promising Future" — 5th Annual 2025 LCOUNCIL Legal and Compliance Summit for the Medical and Pharmaceutical Industry was successfully held in Shanghai. The event was hosted by LCOUNCIL and co-organized by Llinks Law Offices and other partners.
The summit brought together legal experts, corporate compliance officers, and regulatory representatives to engage in in-depth discussions on cutting-edge topics such as AIGC, export controls, anti-unfair competition, clinical trial compliance, License-in/out deals, and trade secrets. The goal was to provide companies with comprehensive solutions, from policy interpretation to practical implementation. Llinks partner Mr. Yiguang Lu was a keynote speaker, while Llinks contractual partner Ms. Susan Deng was invited to moderate a roundtable discussion. They shared their professional insights on key issues including legal risk management for clinical research, volume-based procurement, and specialized anti-corruption enforcement.
Mr. Lu's presentation, titled "Legal Risk Management for Pharmaceutical Companies Sponsoring or Participating in Clinical Research," provided a systematic analysis of compliance points and legal risks throughout the entire clinical trial process. Mr. Lu also offered risk prevention recommendations based on real-world cases. Mr. Lu specifically highlighted common risks in crucial stages such as project approval, ethical review, protecting the rights of subjects, and data management. Mr. Lu emphasized that companies should establish a compliance management system covering the entire lifecycle—from initiation to implementation and conclusion. Mr. Lu stressed that adopting specific measures, such as refining contract design and strengthening CRO collaborations, will enhance a company's ability to manage risks. Mr. Lu's talk provided practical guidance for companies to prevent legal disputes and handle civil litigation and administrative investigations in clinical research.
During the roundtable discussion on "The Development Predicament and Breakthroughs for Medical and Pharmaceutical Companies in a New Environment," Ms. Deng moderated a conversation with multiple industry experts. They analyzed the severe challenges companies currently face from a practical perspective and explored viable solutions and development opportunities, focusing on critical pathways such as internationalization strategies, innovative collaboration models, and optimizing compliance systems.
Llinks is dedicated to providing high-value compliance and legal support to pharmaceutical and medical companies. By building a professional exchange platform and a global network of resources, the firm helps clients both in China and abroad navigate complex regulatory challenges, seize cross-border market opportunities, and secure a firm legal foundation for their continued development in the global pharmaceutical industry.
